Oxford Biomedica plc (LON:OXB - Get Free Report) shares crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 420.59 ($5.29) and traded as high as GBX 426 ($5.36). Oxford Biomedica shares last traded at GBX 421.50 ($5.30), with a volume of 43,576 shares.
Analysts Set New Price Targets
Separately, Deutsche Bank Aktiengesellschaft raised their target price on Oxford Biomedica from GBX 250 ($3.15) to GBX 380 ($4.78) and gave the company a "hold" rating in a report on Tuesday, September 24th.
Read Our Latest Analysis on OXB
Oxford Biomedica Trading Down 0.8 %
The company's fifty day moving average is GBX 420.59 and its 200-day moving average is GBX 371.98. The company has a current ratio of 2.35, a quick ratio of 1.67 and a debt-to-equity ratio of 154.88. The firm has a market capitalization of £444.09 million, a P/E ratio of -292.71 and a beta of 1.09.
Oxford Biomedica Company Profile
(
Get Free Report)
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
Recommended Stories
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
